Dominant negative ADA2 mutations cause ADA2 deficiency in 1

2 heterozygous carriers

- Marjon Wouters¹, Lisa Ehlers^{1,2,3,4,5}, Wout Van Eynde⁶, Meltem Ece Kars⁷, Selket Delafontaine^{1,8}, Verena 3
- Kienapfel^{1,}, Mariia Dzhus¹, Rik Schrijvers^{9,10}, Petra De Haes^{11,12}, Sofie Struyf¹³, Giorgia Bucciol^{1,8}, Yuval 4
- Itan^{6,14,15}, Alexandre Bolze¹⁶, Arnout Voet⁶, Anneleen Hombrouck¹, Leen Moens¹, Benson Ogunjimi^{17,} 5
- 6 ¹⁸ and Isabelle Mevts^{1,8}.
- 7 ¹Laboratory Inborn errors of Immunity, Department of Microbiology, Immunology and
- 8 Transplantation, KU Leuven, Leuven, Belgium
- ² Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite 9
- Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt-10
- 11 Universitat zu Berlin, Berlin, Germany
- ³ Berlin Institute of Health at Charite Universitatsmedizin Berlin, Berlin, Germany 12
- 13 ⁴ German Center for Child and Adolescent Health (DZKJ), partner site Berlin, Berlin, Germany
- 14 ⁵ Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Association, Berlin,
- 15 Germany
- ⁶ Biochemistry, Molecular and Structural Biology, Department of Chemistry, KU Leuven, Leuven, 16
- 17 Belgium
- 18 ⁷ The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai.
- 19 New York City, United States of America
- 20 ⁸ Department of Pediatrics, UZ Leuven, Leuven, Belgium
- 21 ⁹ Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and
- 22 Transplantation, KU Leuven, Leuven, Belgium
- 23 ¹⁰ Department of General Internal Medicine, UZ Leuven, Leuven, Belgium
- 24 ¹¹ Department of Dermatology, UZ Leuven, Leuven, Belgium
- 25 ¹² Department of Microbiology, Immunology and transplantation, KU Leuven, Leuven, Belgium
- 26 ¹³ Molecular Immunology (Rega Institute), Department of Microbiology, Immunology and
- 27 Transplantation, KU Leuven, Belgium
- ¹⁴ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New 28
- 29 York, NY, 10029, USA
- ¹⁵ Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New 30
- 31 York, NY, 10029, USA
- 32 ¹⁶ Helix, San Mateo, CA, United States of America
- ¹⁷ Department of Pediatrics, Antwerp University Hospital, Antwerp, Belgium. 33

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- ¹⁸ Antwerp Center for Translational Immunology and Virology (ACTIV), Center for Health Economics
- 35 Research and Modeling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute,
- 36 University of Antwerp, Antwerp, Belgium
- 37
- 38 [@]: Isabelle Meyts, Herestraat 49 3000 Leuven, Belgium, +3216343841, Isabelle. Meyts@uzleuven.be
- 39 Conflict-of-interest statement:
- 40 LRD KU Leuven receives advisory board honorary from Boehringer-Ingelheim and Takeda for IM.
- 41 IM is the chair of the CSL Behring Chair in Primary Immunodeficiencies, paid to KU Leuven.

42 Abstract

43 Human ADA2 deficiency (DADA2) is an inborn error of immunity with a broad clinical phenotype which encompasses vasculopathy including livedo racemosa and lacunar strokes, as well as hemato-44 45 immunological features. Diagnosis is based on the combination of decreased serum ADA2 activity and 46 the identification of biallelic deleterious alleles in the ADA2 gene. DADA2 carriers harbor a single 47 pathogenic variant in ADA2 and are mostly considered healthy and asymptomatic. However, some 48 DADA2 carriers present a phenotype compatible with DADA2. Here, we report ten patients from seven 49 kindreds presenting with a phenotype indicative of DADA2, in whom only a single pathogenic variant 50 (p.G47R, p.G47V, p.R169Q, p.H424N) was identified. To test whether being heterozygote for specific 51 variants could explain the patients' phenotype, we investigated the effect of the ADA2 missense 52 variants p.G47A, p.G47R, p.G47V, p.G47W, p.R169Q, p.E328K, p.T360A, p.N370K, p.H424N and p.Y453C on ADA2 protein expression, secretion and enzymatic activity. Functional studies indicate that 53 54 they exert a dominant negative effect on ADA2 enzymatic activity, dimerization and/or secretion. At the molecular level, heterozygosity for these variants mimics what is observed in DADA2. We conclude 55 56 that humans with heterozygous dominant negative missense variants in ADA2 are at risk of DADA2.

57 Graphical abstract



- 58
- 59

61 Main text

62 Introduction

63 Human ADA2 deficiency (DADA2) is an inborn error of immunity (IEI) caused by biallelic deleterious mutations in ADA2, characterized by autoinflammation in the form of recurrent fevers and vasculitis 64 ranging from livedo racemosa to lacunar strokes (1, 2). As additional patients have been described, the 65 66 phenotype has expanded to include pure red cell aplasia, various forms of cytopenias and bone marrow failure. Furthermore, lymphoproliferation, hepatosplenomegaly, immunodeficiency with 67 68 hypogammaglobulinemia, sinopulmonary and severe viral infections have been added to the 69 phenotype (3, 4). DADA2 patients can also present with hematological malignancy and hemophagocytosis (5). To date, over 150 pathogenic variants in ADA2 have been described (6). ADA2 70 71 encodes a 59 kD glycoprotein with a signal peptide and a dimerization domain. The theories on disease 72 pathogenesis focus primarily on the reduction or absence of extracellular adenosine deaminase activity due to loss of ADA2 leading to a skewed macrophage development with predominance of 73 74 proinflammatory M1 macrophages (7). The cytokine profile of patients is complex, featuring 75 upregulation of both type I as well as type II interferons (IFNs) alongside to other proinflammatory 76 cytokines (8–10). More recently, Greiner-Tollersrud et al. proposed that ADA2 functions as an 77 adenosine deaminase acting on DNA in the lysosome, where it regulates immune sensing by 78 modulating TLR9 activation (11). Regarding treatment, anti-TNF agents alleviate fever and vasculitis 79 and can prevent strokes in most patients (12). Patients with hematological and immunological manifestations often require hematopoietic stem cell transplantation (13). 80

81 The diagnosis of DADA2 is based on decreased ADA2 serum enzyme activity and the identification of 82 two deleterious alleles in the ADA2 gene (14, 15). A model of genotype / phenotype correlation was 83 proposed, identifying 25% residual adenosine deaminase activity as the pathogenicity threshold when 84 the variant allele was tested in a HEK293T overexpression system (15, 16). In this model, the lowest residual ADA2 activity in the supernatant is associated with the most severe manifestations of DADA2, 85 86 including pure red cell aplasia. The variants were tested in a homozygous state (15, 16). This model 87 suggests that pathogenic variants which result in little or no residual activity, could be pathogenic in 88 heterozygous state, especially since ADA2 functions as a dimer. Interestingly, extended immunophenotyping of carriers of DADA2 (i.e. harboring a single deleterious ADA2 allele) showed an 89 90 intermediate phenotype for several of the features identified in DADA2 patients including SIGLEC-1 91 expression (8).

Diseased carriers of heterozygous variants have already been described in literature, however without
 mechanistic validation. In 2022, Moi. et al. reported a 35-year-old woman presenting with common

94 variable immunodeficiency. Childhood medical history revealed large joint arthritis episodes and 95 recurrent infection. Next-generation sequencing identified her as a heterozygous carrier for the R169Q 96 variant in ADA2. She is the mother of a DADA2 patient, homozygous for the R169Q variant (17). Next, 97 a study performed by the French reference center for autoinflammatory diseases investigated the DNA 98 of 66 patients with clinically suspected DADA2. Three patients were found to be carrier of a heterozygous ADA2 variant. In particular, a heterozygous carrier of G47R presented with an 99 100 inflammatory syndrome characterized by fever and increased CRP levels. Moreover, a papular rash 101 with pruritis and gastrointestinal manifestations were observed (18). In addition, in a Japanese cohort 102 study by Nihira et al. two siblings were reported to suffer from livedo racemosa, renal infarction and 103 neurological manifestations (cerebral infarction and memory disturbance). Next-generation 104 sequencing revealed the presence of a single pathogenic variant E328K (10). Finally, in 2023, Izumo et 105 al. described a 13-year-old girl that was hospitalized with sudden-onset weakness in the right upper 106 and lower limbs caused by a cerebral infarction. Four years earlier, she had presented with livedo. Her 107 treatment included oral anti-platelet drugs and steroid pulse therapy. Additionally, splenic and renal 108 infarction were noted. Measurement of serum ADA2 enzymatic activity revealed levels at 50% of 109 healthy controls. She was diagnosed with polyarteritis nodosa and was treated with prednisone and 110 cyclophosphamide (19). However, she developed a new cerebral infarction and was then started on infliximab. Since then, no reoccurrence of cerebral infarction has been observed. Family history 111 112 revealed that her father had suffered from an acute subarachnoid hemorrhage in his 40s. Sanger 113 sequencing identified the missense variants F355L and Y453C, without functional validation (19).

Our interest in the effect of heterozygous variants was further driven by the finding that in a HEK293T 114 115 overexpression system, the heterozygous ADA2 condition, expressing 50% R169Q ADA2 and 50% wild-116 type (WT) ADA2 resulted in reduced total ADA2 protein secretion compared to the homozygous WT 117 ADA2 condition (20). In addition, in clinical practice, we encountered several patients with a 118 phenotype suggestive of DADA2, in whom we identified only a single deleterious allele.

119 In this report, we describe how specific heterozygous variants cause ADA2 deficiency according to the 120 proposed pathogenicity cut-off (16) through distinct dominant negative effects on either ADA2 enzyme 121 activity, dimerization and/or secretion.

122 Results

123 Clinical phenotype and genotype of reported and suspected DADA2 patients in whom only a 124 heterozygous variant in ADA2 was identified.

125 We identified ten patients, from seven kindreds, with a phenotype suggestive of DADA2, each 126 harboring a single mutation in ADA2, in addition to the patients with heterozygous ADA2 variants

127 retrieved from the literature (10, 17–19). Their pedigrees, clinical features and genetic characteristics 128 are summarized in Figure. 1A, Supplemental Tables. 4-6 and Supplemental Figure. 1. All patients were 129 born to non-consanguineous parents of either Moroccan or Belgian descent. Patient 1 (P1) is the son of patient 2 (P2) (kindred A), and patient 3 (P3) is the daughter of patient 4 (P4) (kindred B). For patient 130 5 (P5) (kindred C) and patient 6 (P6) (kindred D) parental DNA was unavailable. Patient 7 (P7) and 8 131 (P8) are the parents of two previously reported DADA2 patients (kindred E), and patient 9 (P9) is the 132 133 father of two other previously reported DADA2 patients (kindred F). Parental DNA was also unavailable 134 for patient 10 (P10).

135 Five out of ten patients presented with (muco)cutaneous manifestations (Supplemental Table. 4): two 136 with livedo, one with Raynaud phenomenon and two with non-specific cutaneous vasculopathy, 137 including chilblain-like lesions (Supplemental Figure. 1B). Neurological manifestations were observed 138 in three patients: two patients experienced ischemic strokes and brain MRI of P6 revealed white matter 139 lesions. Representative images are shown in Supplemental Figure. 1A and 1C. Immunological and/or hematological manifestations occurred in four patients, including hypogammaglobulinemia in three 140 141 patients, an insufficient pneumococcal antibody response in two patients, neutropenia and thrombocytopenia in P3 and a deep venous thrombosis with pulmonary embolism in P4. Increased 142 143 infectious susceptibility to viral and bacterial infections was noted in three patients. Gastro-intestinal 144 manifestations were present in three patients. P3 experienced abdominal pain, chronic dyspepsia, 145 nodular regenerative hyperplasia and portal hypertension, P9 had abdominal pain and P10 presented 146 with hematemesis. Musculoskeletal symptoms were observed in two patients, both of whom had 147 arthritis, with P10 also experiencing tendinitis. Pericarditis was documented in P10. P7 was the only 148 treated with TNF inhibition (TNFi).

Whole exome sequencing revealed four distinct heterozygous variants in these patients, the p.H424N variant in P1 and P2, the p.G47V variant in P3-5 and P8, the p.R169Q variant in P6 and P7 and the p.G47R variant in P10. Sanger sequencing of gDNA and cDNA confirmed the pathogenic variants identified via whole exome sequencing. No additional pathogenic variants in *ADA2* were identified. Genetic intolerance scores for *ADA2* support ADA2's role as a recessive gene with limited tolerance for variation, but they do not strongly suggest a dominant pathogenic role in heterozygous mutations (Supplemental Table. 7) (21).

To study the potential effect of heterozygous pathogenic variants in ADA2, we examined the four variants, resulting in single amino acid substitutions in different domains of the ADA2 protein, discovered in P1-P10, along with the heterozygous variants reported in the literature (10, 17–19). The variants G47A and G47W were also assessed, as these proven pathogenic variants are located at the

same amino acid position as the G47V and G47R found in P3-5, P8 and P10, respectively (Figure. 1B).

161 Proven pathogenic variants T360A and N370K were also included (16).

162 G47V, R169Q, H424N and Y453C ADA2 variants affect secretion of wild-type ADA2 protein

163 We assessed the effect of ADA2 missense variants on wild-type (WT) ADA2 protein expression, 164 secretion and enzymatic activity. Therefore, we performed transient transfection of each ADA2 variant 165 alone (homozygous), as well as transient co-transfection of each ADA2 mutant together with WT ADA2 166 to mimic the carrier status (heterozygous) (10, 22). Western blotting of cell lysates on denaturating gels showed that in homozygous condition, ADA2 intracellular protein expression levels of most 167 168 studied ADA2 variants were comparable to WT100% ADA2, except for G47A, G47R, G47V and Y453C 169 where there was reduction of 20% compared to WT100% (Supplemental Figure. 2A and B, Supplemental Figure. 3A and B, Supplemental Figure. 4A and B). When we assessed ADA2 secretion in 170 homozygous ADA2 variant conditions, no residual ADA2 secretion was observed for the R169Q and 171 172 Y453C variant (Supplemental Figure. 2A and C). This is in line with the observations by Cheng et al. (23). 173 Compared to WT100%, the secretion of variant H424N was reduced by 80% (Supplemental Figure. 2A 174 and C). A decrease in secretion of around 50% was observed in G47A and G47R when compared to 175 WT100%. The decrease in secretion of variant G47W was more pronounced, with a reduction of 70%. 176 Variant G47V exhibited nearly absent secretion (residual secretion around 10%) (Supplemental Figure. 177 2A and C). Moreover, variants E328K, T360A and N370K showed a reduction of 30%, 20% and 28% in secretion compared to WT100%, respectively (Supplemental Figure. 2A and C, Supplemental Figure. 178 179 4A and C). Variant F355L exhibited normal protein secretion compared to WT100% (Supplemental 180 Figure. 3A and C).

When ADA2 variants were transfected in a heterozygous setup with WT ADA2, we observed a decrease in secretion across all variants except for E328K, F355L, T360A and N370K, when compared to WT50% (Supplemental Figure. 2A and D, Supplemental Figure. 3A and D, Supplemental Figure. 4A and D). While the secretion of ADA2 was only reduced by around 10% for variants G47R, G47V and Y453C, and 20% for G47A and G47W, the reduction below WT50% was more pronounced for R169Q and H424N with a reduction of 70% and 35% respectively (Supplemental Figure. 2A and D). Taken together, our data suggest a dominant negative effect of ADA2 variants R169Q and H424N on WT ADA2 secretion.

Since ADA2 dimer formation is required for ADA2 deaminase activity (24), we next assessed the secreted ADA2 dimer formation of each variant in both homozygous and heterozygous conditions in non-denaturating gels. In homozygous setting, F355L shows normal dimer secretion in homozygous conditions (Supplemental Figure. 5A and B). Variant G47A, G47R and G47W show a residual ADA2 dimer secretion of around 48%, 53% and 9% respectively compared to WT100% (Figure 2A and B).

193 However, no ADA2 dimers were detected in the supernatant of the homozygous G47V, R169Q, E328K,

194 H424N and Y453C transfection setting (Figure. 2A and B). More interestingly, expression of variants

195 T360A and N370K led mostly to secretion of monomeric ADA2 (Supplemental Figure. 6A and B).

In heterozygous setup (WT/M) G47A, G47R, G47W, E328K, T360A and F355L ADA2 variants result in levels of dimer secretion comparable to WT50% (Figure. 2A and C, Supplemental Figure. 4A and C). A small reduction in dimer secretion of 10% was observed in WT/G47V and WT/N370K (Figure. 2A and C, Supplemental Figure. 4A and C). However, R169Q, H424N and Y453C showed a 60%, 50% and 35% decrease respectively in ADA2 dimer secretion when compared to WT50% (Figure. 2A and C). This observation further supports the hypothesis that R169Q, H424N and Y453C exert a dominant negative effect on WT ADA2.

Enzymatic activity of WT ADA2 is affected in a dominant negative manner by G47A, G47R, G47V, R169Q, E328K, H424N and Y453C ADA2 variants in overexpression

205 Next, the ADA2 enzymatic activity of each ADA2 variant was evaluated. We observed normal ADA2 206 enzymatic activity for variant F355L (Supplemental Figure. 7). In the homozygous conditions, a 207 reduction of intracellular ADA2 enzymatic adenosine deaminase activity was observed in all other ADA2 variants studied, when compared to 100% WT ADA2 (Figure. 3A, Supplemental Figure. 8A). For 208 209 G47A, G47R, G47V and R169Q the residual enzymatic activity was around 25% compared to WT100%. Variant T360A and N370K show a residual enzymatic activity of 35% and 20% respectively. This 210 211 reduction was even more pronounced in variants G47W, E328K, H424N and Y453C, where the residual 212 enzymatic activity was only 8%, 7%, 11% and 7,5% respectively (Figure. 3A, Supplemental Figure. 8A). 213 When ADA2 activity of secreted homozygously expressed ADA2 variants was examined, G47A,G47R, 214 T360A and N370K showed 25%, 6%, 8% and 7% residual enzymatic activity respectively (Figure. 3B), 215 Supplemental Figure. 8B). However, G47V, G47W, R169Q, E328K, H424N and Y453C exhibited nearly 216 absent enzymatic activity.

In heterozygous conditions, variants G47W, T360A and N370K did not affect the enzymatic activity of
WT ADA2 (Figure. 3C and D, Supplemental Figure. 8C and D) unlike G47A, G47R, G47V, R169Q, E328K,
H424N and Y453C which resulted in enzymatic activity levels below that of the 50% ADA2 WT gene
product, suggesting a dominant negative effect. Based on the effect on WT ADA2 enzymatic activity,
we made a distinction between absent dominant negative effect (enzymatic activity >75% of WT50%),
a weak dominant negative effect (enzymatic activity 50-75% of WT50) and a strong dominant negative
effect (enzymatic activity 0-50% of WT50) as described before (16, 25).

225 Variants G47A, G47R, G47V and E328K exert a weak dominant negative effect on the enzymatic activity 226 of WT ADA2 both intracellularly as assessed in the whole cell lysate and extracellularly as secreted 227 ADA2 in the supernatant, with a residual enzymatic activity below 75% (Figure. 3C and D). The weak 228 dominant negative effect is most pronounced in the supernatant of variant G47V, with a residual 229 activity of 58% compared to WT50. More interestingly, variant R169Q exhibits a weak dominant 230 negative effect on intracellular ADA2, however it exerts a strong dominant negative effect on the 231 enzymatic activity of secreted WT ADA2 with a residual activity of only 23% (Figure. 3C and D). This is 232 in line with the decrease in dimer secretion observed in the heterozygous R169Q condition. 233 Furthermore, variant H424N has a strong dominant negative effect on both intracellular as well 234 secreted WT ADA2 enzymatic activity (Figure. 3C and D). This suggests that, in addition to hindrance 235 of ADA2 secretion (Figure. 2), there is also an intrinsic inhibition of the WT ADA2 activity. Lastly, variant 236 Y453C exhibits a strong dominant negative effect with a residual activity of only 41% compared to 237 WT50 both intracellularly in the whole cell lysate as well as extracellularly on secreted ADA2 (Figure. 238 3C and D).

239

240 Prediction model of ADA2 dimer formation in the presence of ADA2 variants

Molecular dynamics (MD) simulations indicate the contributions of amino acid residues to the stability and conformational dynamics of the complex. To investigate these dynamics within the ADA2 complex, three independent 100 ns MD simulations for both the monomeric WT and mutated ADA2 were performed. After completing the simulations, the B-factors for each individual monomer, which serve as a measure of atomic fluctuation within the structure, were calculated. These B-factors were averaged across all monomers and normalized by comparing them to those obtained from the WT simulations, allowing for a relative assessment of the fluctuation.

248

249 All variants except Y453C result in increased fluctuation in their immediate vicinity and thereby 250 demonstrate increased structural instability (Figure. 4A). Notably, the variants at residues G47 and 251 H424 exhibit heightened fluctuation, particularly in regions corresponding to the dimer interface. This 252 increase in fluctuation may explain the observed decrease in deaminase activity when these variants 253 occur as it may prevent correct folding, leading to aggregation or the formation of the dimer interface. The pathogenic variant R169Q also exhibited heightened fluctuation; however, given its distance from 254 255 the interface, or the active site, this results in disrupted folding/stability. In the WT structure, R169 256 stabilized the fold with a salt bridge with residue D179, hydrogen bonds with residue T129 and aromatic stacking between the guanidinium group of residue R169 and the aromatic ring of residue 257 258 Y130 (Figure. 4B). All three are disrupted upon mutation. This impairment could be due to the change from a positively charged side chain to an uncharged, shorter side chain, and thus losing interactions 259

260 with its neighboring residues. Similarly, variant E328K, which is located in the vicinity of the active site 261 will lead to a disruption of a three strong hydrogen bonds with residues N370, G358 and E359, the 262 latter being essential for catalytic activity (24), leading to loss of structural stability as well as catalytic 263 activity (Figure. 4C). The variant Y453C showed a slight decrease in fluctuation in its immediate vicinity 264 (Figure. 4A). However, due to its distance from the active site or dimerization interface, this is not 265 expected to have an effect on either. In the WT structure, Y453 stabilizes the fold with a hydrogen 266 bond with E94, which is lost upon mutation (Figure. 4D). This mutation to a smaller sidechain with loss 267 of interactions is expected to disrupt the folding.

268

Serum ADA2 enzyme activity of diseased heterozygous carriers of pathogenic ADA2 variants is in the carrier range

To assess whether the dominant negative effect of the indicated variants could be discriminated from the patients' sera, we measured the ADA2 enzyme activity in the serum of the 10 suspected DADA2 patients. All ADA2 enzyme activity levels were in the range of the heterozygous carriers of pathogenic DADA2 variants (Figure. 5A). While the serum ADA2 activity levels of P4, P5 and P7 were in the lower range of DADA2 carriers, we observed that the serum ADA2 activity levels of P1, P2 and P5 were in the higher carrier range (Figure. 5A). Serum ADA2 levels analyzed by Western Blot showed that ADA2 secretion correlated with the serum residual ADA2 enzymatic activity (Figure. 5B- D).

278 Population genetics and correlation with phenotypes

279 Next, we investigated the frequency of the identified dominant negative ADA2 variants in the general 280 population by looking at the frequency in the overall gnomAD v4.1.0 samples, and by genetic ancestry 281 (Supplemental Table. 8). We found 1,262 alleles for these variants in gnomAD v4. None of the variants 282 were found at the homozygote state implying that about 0.16% of the general population (1,262 out 283 of 807,088 sequenced at this locus) is heterozygote for a dominant negative variant in ADA2. The most 284 common variant was R169Q, which has a prevalence above 1 in 1,000 in the European Finnish and 285 non-Finnish genetic ancestry groups. Of note, both p.G47R missense variants were most common in 286 the Middle Eastern and South Asian ancestry groups with an allele frequency close to 1 in 1,000.

Given the relatively high number of individuals in the UK Biobank and from the Finnish population with a R169Q variant, we sought to investigate the clinical impact of these variants in the UK Biobank (26, 27) and in Finngen (28). For the UK Biobank, variant-level pheWAS results were available via two different publicly available resources: (i) Genebass (https://app.genebass.org/) calculated associations for 4,529 phenotypes across 394,841 individuals, and (ii) AZ pheWAS portal (https://azphewas.com/) calculated associations for ~13K binary and ~5K continuous phenotypes across ~500,000 whole-

293 genome sequenced individuals and reported those with a p<0.01. For Finngen, we utilized the data 294 freeze 12 results (available on November 4, 2024), which include association results for 2,502 295 phenotype endpoints across 500,348 individuals. We focused our analysis of these results to phenotypes known to be relevant to DADA2, and grouped them based on the organs impacted in order 296 297 to make it easier to compare the results of the three pheWAS analyses, which used different 298 phenotype definitions. For each of the DADA2 phenotypes, we looked whether cases were enriched in 299 R169Q heterozygotes (Table. 1). Several neurological manifestations compatible with DADA2 were 300 more frequent in R169Q heterozygotes, including stroke, sequelae of cerebrovascular disease and 301 headaches. Vascular dementia was also more frequent. We also observed enrichment related to 302 cutaneous vasculopathy such as vasculitis and Raynaud phenomenon, as well as immunological and 303 bone marrow manifestations. Hodgkin lymphoma and myeloid leukemia were also identified during 304 our search which both have been described in DADA2 patients (4, 29–31). We also found DADA2 305 phenotypes that were not enriched, such as viral warts and cytomegaloviral disease (32, 33).

306 To investigate the effect of heterozygous pLOF ADA2 variants in general, we studied the phenotypic 307 associations of collapsed pLOF ADA2 variants in the Bio*Me* BioBank rare 308 (https://icahn.mssm.edu/research/ipm/programs/biome-biobank/) and the UK Biobank (34). The 309 PheWAS identified several phenotypic associations of ADA2 pLOFs that align with ADA2 function and 310 clinical presentation of individuals with autosomal recessive DADA2, including diseases of spleen, 311 abnormal results of study function of liver, transient occlusion of retinal artery, abnormal coagulation 312 profile, cranial nerve disorders, paraplegia and diplegia, granulomatous disorders of skin, ulcerative 313 colitis and elevated blood pressure (Supplemental Figure. 9A and B and Supplemental Data File 5 and 314 6). In conclusion, data from population genetics are supportive of a DADA2 disease state in distinct 315 heterozygous carriers.

316 Discussion

317 Here we report a cohort of heterozygous carriers of pathogenic ADA2 variants presenting with DADA2 318 clinical features. In vitro study of the ADA2 variants identified in this patient cohort revealed that 319 R169Q, H424N and Y453C affect secretion of WT ADA2 protein. Moreover, we demonstrate a 320 dominant negative effect on the enzymatic activity of WT ADA2 by variants G47A, G47R, G47V, R169Q, 321 E328K, H424N and Y453C both intracellularly and extracellularly. Using the HEK293T overexpression 322 model, biochemical modeling and population genetics, we provide proof of principle for the observation that heterozygous carriers of ADA2 variants can be diseased. In two of the pedigrees, there 323 324 is an autosomal dominant (AD) pattern of DADA2, albeit with incomplete penetrance. To highlight that 325 the dominant negative effect is variant-specific, we also functionally evaluated ADA2 variants that have

326 no dominant negative effect and that are only pathogenic in homozygous or compound heterozygous 327 state with another pathogenic variant. For variant G47W, the change of a small amino acid (glycine) to 328 a large hydrophobic amino acid (tryptophan) could prevent correct folding which in turn could affect 329 the protein stability and formation of both homodimers as well as heterodimers with WT ADA2. 330 Variants T360A and N370K appeared to be normally secreted, however when secretion of ADA2 dimers was assessed, mainly monomeric ADA2 was detected. This could explain that when present in a 331 332 homozygous condition, low residual enzymatic activity is observed, since dimer formation is essential 333 for full adenosine deaminase activity (24).

334 Our study has important clinical implications. First, we provide experimental evidence for the clinical 335 observation of DADA2 disease in heterozygous carriers in the well-established HEK293T 336 overexpression model (16). Based on Jee et al., the carrier frequency of pathogenic ADA2 variants is 337 estimated to be 1 in 236 when 25% residual enzymatic activity in overexpression is used as cut-off to 338 determine deleterious variants (15). The HEK293T cell overexpression model to study the impact of 339 suspected pathogenic variants has shown that variants associated with disease have variable residual 340 enzyme activity in the supernatant (15, 16). However, although several publications mention disease 341 status in heterozygous carriers (10, 17–19), a potential mechanism has not been explored. Our study 342 shows that different variants exert distinct effects on the WT ADA2 glycoprotein in overexpression. 343 Some variants affect WT ADA2 because of their intrinsic defect in enzymatic activity. Presumably they 344 affect WT ADA2 enzymatic activity when they are assembled with WT ADA2 into a dimer complex. 345 Dimer formation of WT ADA2 with ADA2 variants G47A, G47R, G47V and E328K results in weak 346 dominant negative effect on WT ADA2. When ADA2 variant H424N is built in together with WT ADA2 347 to form a dimer, the impact on WT ADA2 is more important resulting in a strong dominant negative 348 effect. Other variants affect WT ADA2 by trapping WT ADA2 intracellularly resulting in decreased 349 secretion of WT ADA2 protein and in this way also affects extracellular ADA2 enzymatic activity in a dominant negative manner, as is the case for ADA2 variant R169Q. Beside the in vitro exploration, we 350 351 studied population databases. Data from PheWAS show that the heterozygous state for pLOF variants 352 in ADA2 is indeed associated with phenotypes that align with DADA2. When studying the most 353 frequent allele, R169Q, the enriched phenotypes are even more striking, despite the overall low 354 number of cases. Although some phenotypes are soft and subjective like headache, some, like 355 idiopathic thrombopenia and stroke and are more specific and objective. Our data invite therefore to 356 revise the approach to carriers of pathogenic variants for which we describe here a dominant negative 357 effect.

Moreover, our findings stress once again the importance of functional validation of ADA2 variants. Izumo et al. describe a patient with typical DADA2 features yet with serum ADA2 enzymatic activity in

carrier range. Two missense variants (F355L and Y453C) were identified (19). However, we show that
variant F355L exhibits normal ADA2 enzymatic activity and is normally expressed and secreted. Our
data suggest that the Y453C variant is the driving pathogenic variant through dominant negative effect.
Likewise another report presents a 22-year-old DADA2 patient who harbors two missense variants,
E328K and F355L. Based on our findings, F355L is likely not responsible for the phenotype observed in
this patient (35).

366 Unfortunately, the disease status of carriers cannot be derived in a straightforward way from serum 367 enzyme activity. Indeed, we observed variable ADA2 enzyme activity in the serum of diseased carriers. 368 However, as remarked by Lee and colleagues, the use of the HEK293T overexpression system allows 369 to increase the dynamic range of the measurements. Moreover, current techniques used to measure 370 ADA2 activity in serum are unable to resolve small differences in activity (16). For that reason, the 371 clinical samples of our patients are not able to reflect the findings from the overexpression system. A 372 future more sensitive assay, or a combination of assays or, if feasible, an omics approach may aid in discriminating diseased carriers from patients. In the same way, we previously published that the 373 374 phenotype and function of lymphocytes from heterozygous carriers were often intermediate to that 375 of healthy donors and ADA2-defcient patients (8). Carmona-Rivera et al. observed increased low 376 density granulocytes in a heterozygous carrier with adult onset polyarteritis nodosa, when studying 377 the role of neutrophils in DADA2 (36).

378 Interestingly, unlike autosomal recessive (AR) patients harboring homozygous or compound 379 heterozygous pathogenic variants, the patients with heterozygous variants and therefore AD DADA2 380 seem to present DADA2 manifestations later in life. Indeed, except for P1, P3 and P5, all patients 381 presented after the first decade. We can imagine a situation in which the entire genetic make-up but 382 also the exposure to environmental triggers, like infection or vaccination, tip the balance to the onset 383 of clinically overt inflammation. In addition, by inflammaging, heterozygous carriers of dominant 384 negative ADA2 variants may naturally evolve towards a DADA2 phenotype (37). Also, except for two 385 patients with a heterozygous R169Q variant presenting with hypogammaglobulinemia and 386 lymphopenia, no cytopenia was observed and most clinical manifestations consisted of vasculitis. This 387 is in line with the proposition by Lee et al. where the lowest residual ADA2 enzyme activities are linked 388 to bone marrow phenotype and the higher residual ADA2 enzyme activities are linked to vasculitis or 389 vasculopathy (16). Of course, it cannot be excluded that modifier genes are at play or that a second hit 390 in a hitherto undefined gene causes the phenotype in these heterozygous carriers, as is the case in a 391 recent paper by Ahn et al (38). Finally, there remains the possibility that monoallelic expression plays 392 a role, although ADA2 is not listed amongst the genes exhibiting this expression pattern (39, 40). The 393 same hypotheses can be put forward to explain the incomplete penetrance of the phenotype in the

394 heterozygous carriers of the dominant negative variants.

Our findings also have important implications for the choice of hematopoietic stem cell donors. Until now, there is debate as to whether procedures with heterozygous carrier donors have worse outcome. However, it can be considered safer to select a matched unrelated donor in cases of siblings carrying monoallelic mutations in ADA2 (13, 41). Our data show that the decision to opt for a matched carrier of a heterozygous variant as donor may depend on the specific variant, highlighting the essence of studying the pathogenicity of a given variant.

401 Our investigations are hampered by our incomplete understanding of the pathophysiology of DADA2. 402 It is still unclear what the physiological function of ADA2 is and whether the intracellular or 403 extracellular fraction is more important. Until now diagnosis of DADA2 has consisted of identification 404 of two known pathogenic variants or variants of uncertain significance combined with the detection 405 of significantly reduced or absent ADA2 activity in the serum or plasma (3, 14). The new data on the 406 lysosomal role of ADA2 further complicate the view on the pathophysiology of this condition and 407 further research is needed to align the prevailing disease models (11). Nevertheless, the finding by 408 Greiner-Tollersrud et al. that the deaminase activity of ADA2 positively correlates with the DNA binding 409 / editing activity stresses the importance of our findings (11).

410 Our data also imply that the incidence of AD and AR ADA2 deficiency is higher than the published 1 in 411 222,164 individuals (15). Indeed, the variants we describe as having a dominant negative effect 412 represent a significant fraction of pathogenic variants. Based on a narrative review by Dzhus et al. in 413 which 495 DADA2 patients reported in literature were included, we calculated the frequency of each variant in the DADA2 patient population (42). Variant G47R (found in P10 of our cohort) is the most 414 415 common, present in 27% of the patients. R169Q was found in 17% of the patients. G47A, G47V, G47W, 416 E328K and Y453C were more rare, only present in 2%, 3%, 1%, 0,6% and 6% respectively (42). As such, 417 the findings of our work are relevant for an important proportion of DADA2 patients' kindreds. For 418 optimal family counseling, an effort will need to be undertaken to test all variants in heterozygous 419 setting to establish whether they can act in a dominant negative mechanism and cause AD inheritance.

Finally, the question is whether heterozygous patients harboring a single pathogenic *ADA2* variant with a proven dominant negative effect should receive treatment as for AR DADA2. Given the high proportion of patients (three out of ten in our cohort and three out of seven previously reported in literature) with CNS vascular events as well as renal / splenic infarction (one out of seven previously reported in literature), our findings invite for a reconsideration of treating carriers of dominant negative ADA2 variants with TNFi, as per current guidelines for AR ADA2.

427 Materials and Methods

428 Patient selection and variant inclusion

This study was approved by the Ethics Committee for Research of Leuven University Hospitals (project numbers: S51577, S63077). Patients were selected based either on clinical phenotype fitting DADA2. In other cases, symptomatic parents of DADA2 patients were included. In addition, we studied the variants in previously reported patients with a DADA2 phenotype, harboring each a single deleterious variant (10, 17–19). G47A, G47W, T360A and N370K, proven pathogenic variants in homozygous setting, were also included (16).

435 ADA2 sequencing

Whole exome sequencing (WES) was performed in all patients (Genomics Core Leuven, KU Leuven,
Belgium). ADA2 mutations were identified by targeted Sanger sequencing on genomic DNA (in P1-3,
P5, P6, P8 and P9) and copy DNA (in P1-3, P5-8) (LGC Genomics). Additional non-pathogenic SNPs
observed in ADA2 are presented in Supplemental Table. 1. Primers of targeted Sanger sequencing are
available upon request.

441 Plasmid construction

442 ADA2 variant constructs were generated by Q5 site-directed mutagenesis (SDM; New England Biolabs) 443 with human wild-type (WT) ADA2 pCMV6 myc-DKK-tagged plasmid (ADA2 transcript 3, 444 NM_001282225 Origene, Cat# RC238645) as backbone. SDM primer sequences designed with 445 NEBaseChanger are provided in Supplemental Table. 2. Plasmids were amplified in heat shock 446 transformed *E.coli* and purification was performed with QIAprep spin Miniprep kit (QIAgen) according 447 to manufacturer's instructions. Presence of the introduced variants in the plasmids were verified by 448 Sanger sequencing (LGC Genomics).

449 Cell culture and transfection

Human embryonic kidney (HEK) 293T cells were seeded at 2,5x10⁵ cells/6-well in 2ml 24h prior to transfection. Cells were transfected with 25ng of WT and 25ng of mutant *ADA2* plasmids for carrier conditions or 50ng with WT or mutant ADA2 plasmids for homozygous conditions, respectively, using Lipofectamine 2000 Transfection Reagent (Thermofisher Scientific) according to manufacturer's instruction. Medium was changed 24h after transfection. After 48h, cells and supernatant were collected.

456 Western Blotting with Denaturating gel

457 Transfected cells were collected after 48h and whole cell lysate was obtained by lysing cells in 100µl 458 NP-40 buffer (150 mM NaCl, 50 mM Tris-HCl, 1% NP-40, pH 7.4) supplemented with protease inhibitor 459 (Thermo Fisher Scientific). Equivalent amounts of protein were supplemented with 4x Bolt LDS sample buffer (Thermo Fisher Scientific) and 1x Bolt sample reducing agent (Thermo Fisher Scientific). 460 Supernatant from transfected HEK293T cells were diluted 1:7 in 2x Bolt LDS sample buffer and 1x Bolt 461 sample reducing agent (Thermo Fisher Scientific). Equivalent amounts of serum were diluted in in 2x 462 463 Bolt LDS sample buffer and 1x Bolt sample reducing agent (Thermo Fisher Scientific) Supplemented 464 lysates and supernatant were denaturared at 70°C for 5min prior to separation on a 4-12% Bis-Tris 465 acrylamide gel. SeeBlue™ Plus2 Pre-stained Protein Standard (Thermo Fisher Scientific) was used as 466 protein molecular weight marker. Proteins were transferred on a PVDF membrane (Thermo Fisher 467 Scientific) and blocked with 5% bovine serum albumin (BSA) in Tris Saline. Membranes were 468 subsequently probed with ADA2 primary antibody (Abcam, ab288296, 1/1000) overnight at 4°C. Membranes were washed and incubated with HRP-conjugated secondary goat anti-rabbit (Abcam, 469 470 ab205718, 1/5000) for 1h at room temperature. Anti B-actin antibody (Sigma, A5441, 1/9000) was 471 used as loading control. Pierce ECL western blotting substrate (Thermo Fisher Scientific) and 472 SuperSignal West Pico PLUS Chemiluminescent substrate (Thermo Fisher Scientific) were used to 473 visualize HRP activity. Chemiluminescent signals were detected with a ChemiDoc XRS + Imaging system 474 (Bio-rad) and Image lab 6.0.1 Software was used for densitometric quantification.

475 Western Blotting with Native gel

476 Intracellular dimer formation and dimer secretion were analysed on NativePAGE[™] 4 to 16%, Bis-Tris 477 (Thermo Fisher Scientific). Equivalent amounts of protein were supplemented with 5% NativePAGE G-478 250 Sample additive (Thermo Fisher Scientific), 4x NativePAGE sample buffer (Thermo Fisher 479 Scientific), and 1x NativePAGE sample buffer (Thermo Fisher Scientific). Supernatant was diluted 1:4 480 in 5% NativePAGE G-250 Sample additive (Thermo Fisher Scientific), 4x NativePAGE sample buffer 481 (Thermo Fisher Scientific), and 1x NativePAGE sample buffer (Thermo Fisher Scientific). Gel 482 electrophoresis was performed in accordance to manufacturer's instructions. NativeMark™ Unstained 483 Protein Standard (Thermofisher Scientific) was used as protein molecular weight marker. Proteins were transferred on a PVDF membrane (Thermo Fisher Scientific) in the presence of NuPAGE transfer 484 485 buffer supplemented with 10% methanol. Protein standard (Thermofisher Scientific) was visualized 486 using ponceau S solution (Abcam). Blocking and antibody probing was performed as described 487 previously.

488 Molecular modeling

489 The crystal structure and mutated structures of the human ADA2 dimer were prepared using 3D 490 protonation and energy minimization with MOE v.2022.2 (Molecular Operating Environment (MOE), 491 2024.0601 Chemical Computing Group ULC, 910-1010 Sherbrooke St. W., Montreal, QC H3A 2R7, 492 2024.); however, only the monomeric form was retained for simulations. Prior to performing triple 493 molecular dynamics (MD) simulations with GROMACS v.2022.3 (43), the CHARMM-GUI webserver (44, 494 45) was utilized to set up the system, incorporating the 4-point rigid water model (OPC)(46), the ff19SB 495 force field for the protein (47), and the 12–6–4 Lennard-Jones potential model for divalent ions (48). 496 Hydrogen mass repartitioning was applied to the complex to enhance simulation stability without 497 affecting the kinetics of the trajectory or conformational sampling (49, 50).

The complexes were placed at the center of a cubic simulation box with a minimum distance of 1 nm from the box boundaries. The system was then solvated with water and neutralized with Cl⁻ and Na⁺ counter ions, followed by energy minimization using the steepest descent method (51). Interactions were calculated using the Verlet cutoff scheme (52) and the Particle Mesh Ewald (PME) coulomb type (53). The LINCS algorithm was employed to constrain bond lengths (54).

503 Subsequent to energy minimization, the system was equilibrated to 300 K and 1000 kg/m³ using a 100 504 ps V-rescale thermostat under an NVT ensemble, followed by a 100 ps equilibration under an NPT 505 ensemble with a V-rescale thermostat and C-rescale barostat (55, 56) . Positional restraints were 506 applied to the complex during equilibration. The Parrinello-Rahman barostat (57) was utilized for 507 pressure control during the production run.

Figures were made using PyMOL (The PyMOL Molecular Graphics System, Version 3.0 Schrödinger,LLC.).

510 **Population genetics**

511 For variant p.R169Q, we looked at the three variant-based phenome wide association studies 512 (pheWAS) results as calculated and reported in GeneBass (https://app.genebass.org/) (26), AZ PheWAS 513 https://azphewas.com/) (27) and in Finngen data freeze 12 514 (https://www.finngen.fi/en/access results) (28). Genebass is a resource of exome-based association 515 statistics, made available to the public. The dataset encompasses 4,529 phenotypes with gene-based 516 and single-variant testing across 394,841 individuals with exome sequence data from the UK Biobank 517 (26). AZ PheWAS makes use of the UK Biobank 500k WGS (v2) Public (27). We used the subset of the 518 ~500,000 whole genome sequenced participants released by the UK Biobank that are high quality and 519 predominantly unrelated to evaluate the association between protein-coding variants with ~13K 520 binary and ~5K continuous phenotypes using variant-level and gene-level phenome-wide association 521 studies in 6 ancestry groups (European, Askenazi Jewish, Admixed American, African, East Asian, South

Asian). A small number of potentially sensitive phenotypes have been excluded. This portal contains the subset of variant-level associations for which $p \le 0.01$ and the subset of gene-level associations for which $p \le 0.1$. Only variants identified in at least 20 samples were included in the variant-level analysis. Please note that no LD pruning has been performed on these associations. The full pheWAS results for p.R169Q are present in Supplemental Data File 1, 2 and 3.

527 The BioMe BioBank comprises exome sequencing data and electronic health records from 30,813 528 genetically diverse participants recruited through Mount Sinai Hospital's primary care clinics. For the 529 UK Biobank analysis, we utilized 200K exome sequences from participants of European ancestry and 530 their electronic health records. Given the low allele frequency of pathogenic ADA2 variants in the 531 population, we collapsed all heterozygous ADA2 variants predicted to have a loss-of-function effect (pLOF) as determined by LoGoFunc (58) and LOFTEE (59) and performed two gene-based phenome 532 533 PheWAS in the BioMe BioBank and the UK Biobank (Supplemental Data File 4). We used Firth's logistic 534 regression for binary phenotypes obtained from ICD-10 codes matching DADA2 phenotypes (Supplemental Table. 3) and mapped to phecodeX (60) and linear regression for quantitative 535 536 phenotypes that were curated from laboratory measurements and vital signs. All analyses were 537 adjusted for, age, sex and first ten genetic principal components as covariates.

538 ADA2 enzyme assay

Adenosine deaminase 2 activity was determined in whole cell lysates and supernatant from HEK293T cells overexpressing ADA2 as well as in human serum. Adenosine deaminase activity was measured in a colorimetric assay adapted from Giusti and Galanti (61). To inhibit ADA1 activity, Erythro-9-(2hydroxy-3-nonyl) adenine (EHNA) was used. Triplicate measurements were performed for all samples. Enzymatic activity of ADA2 variants overexpressed HEK293T cells was normalized to the activity of WT ADA2.

545 Statistical analysis

Quantification of Western blotting and ADA2 enzyme assay data were presented as mean ± standard
deviation (SD). Differences between controls and patient populations were statistically assessed using
the Mann-Whitney U test. P-values less than 0.05 were considered statistically significant.

549 Data availability

550 Source data are provided in the Supporting Data values file. Additional data can be obtained upon 551 request to the corresponding author.

552 Author contributions

IM, LM, AH, and MW. conceptualized and designed this work. IM, LM, BO, AH, AV, AB, YI, MD, VK, SD,
MEK, WVE, LE and MW performed the experiments and carried out data acquisition. BO, GB, PDH and
RS provided patient samples. IM, LM, AB, SD, MEK, WVE and MW wrote the manuscript. All authors
edited the paper.

557 Acknowledgments

IM is a Senior Clinical Investigator at the Research Foundation FWO – Flanders, and is supported by 558 559 the CSL Behring Chair of Primary Immunodeficiencies through KU Leuven, by the FWO Grants 560 G0C8517N, G0B5120N and G0E8420N and by the Jeffrey Modell Foundation. This project has received 561 funding from the European Research Council (ERC) under the European Union's Horizon 2020 research 562 and innovation programme (grant agreement No. 948959). This work is supported by ERN-RITA. LE was 563 supported by a PhD Fellowship from the Research Foundation FWO – Flanders (grant 11E0123N). LE is 564 a fellow of the BIH Charité Junior Clinician Scientist Program funded by the Charité -565 Universitätsmedizin Berlin, and the Berlin Institute of Health at Charité (BIH). MEK and YI were funded 566 by the Charles Bronfman Institute for Personalized Medicine at Icahn School of Medicine, Mount Sinai. 567 This work was supported in part through the computational and data resources and staff expertise 568 provided by Scientific Computing and Data at the Icahn School of Medicine at Mount Sinai and supported by the Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the 569 570 National Center for Advancing Translational Sciences. This research was conducted using the UK 571 Biobank resource under application number 53074. WVE acknowledges funding of FWO Grant 572 G095522N was used for this research. RS is supported by an FWO senior clinical investigator fellowship 573 (1805523N).

574 **References**

575 1. Zhou Q, et al. Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. *New England* 576 *Journal of Medicine*. 2014;370(10):911–920.

577 2. Navon Elkan P, et al. Mutant Adenosine Deaminase 2 in a Polyarteritis Nodosa Vasculopathy. *New* 578 *England Journal of Medicine*. 2014;370(10):921–931.

3. Wouters M, et al. Human ADA2 Deficiency: Ten Years Later. *Curr Allergy Asthma Rep.* 2024;
24(9):477-484.

4. Gardner LS, et al. Development of EBV Related Diffuse Large B-cell Lymphoma in Deficiency of
 Adenosine Deaminase 2 with Uncontrolled EBV Infection. *J Clin Immunol*. 2024;44(5):118.

583 5. Lee PY, et al. Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International
584 Consensus Statement. *JAMA Netw Open*. 2023;6(5):e2315894.

medRxiv preprint doi: https://doi.org/10.1101/2024.12.09.24317629; this version posted December 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 585 6. Van Gijn ME, et al. New workflow for classification of genetic variants' pathogenicity applied to
 586 hereditary recurrent fevers by the International Study Group for Systemic Autoinflammatory Diseases
 587 (INSAID). *J Med Genet*. 2018;55(8):530–537.
- 7. Zavialov A V., et al. Human adenosine deaminase 2 induces differentiation of monocytes into
 macrophages and stimulates proliferation of T helper cells and macrophages. *J Leukoc Biol.*2010;88(2):279–290.
- 8. Yap JY, et al. Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and
 Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2
 Deficiency. *J Clin Immunol*. 2021;41(8):1915–1935.
- 594 9. Belot A, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood.
 595 *Pediatric Rheumatology*. 2014;12(1). https://doi.org/10.1186/1546-0096-12-44.
- 10. Nihira H, et al. Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency
 reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation. *Journal of Allergy and Clinical Immunology*. 2021;148(2):550–562.
- 599 11. Greiner-Tollersrud OK, et al. ADA2 is a lysosomal deoxyadenosine deaminase acting on DNA
 600 involved in regulating TLR9-mediated immune sensing of DNA. *Cell Rep.* 2024;43(11):114899.
- 12. Deuitch NT, et al. TNF inhibition in vasculitis management in adenosine deaminase 2 deficiency
 (DADA2). *Journal of Allergy and Clinical Immunology*. 2022;149(5):1812-1816.e6.
- 13. Hashem H, et al. Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency:
 Report on 30 Patients. *J Clin Immunol*. 2021;41(7):1633–1647.
- 14. Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): Updates on the phenotype,
 genetics, pathogenesis, and treatment [preprint]. *J Clin Immunol*. 2018;38(5):569–578.
- 15. Jee H, et al. Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency
 driven by a function-based approach. *Journal of Allergy and Clinical Immunology*. 2022;149(1):379–
 387.
- 610 16. Lee PY, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine
 611 deaminase 2 (DADA2). *Journal of Allergy and Clinical Immunology*. 2020;145(6):1664-1672.e10.
- 612 17. Moi L, et al. Common Variable Immunodeficiency in a Carrier of the ADA2 R169Q Variant:
 613 Coincidence or Causality?. *J Clin Immunol*. 2022;42(5):959–961.
- 18. Rama M, et al. A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2
 (DADA2): A French reference centres experience. *European Journal of Human Genetics*.
 2018;26(7):960–971.
- 19. Izumo H, et al. A Successful Infliximab Treatment of a Pediatric Case of Severe Polyarteritis Nodosa
 With a Cerebral Infarction and a Decreased Adenosine Deaminase 2 Activity. *Cureus*.
 2023;15(10):e47952.
- 62020. Ehlers L, et al. Human ADA2 deficiency is characterized by the absence of an intracellular621hypoglycosylated form of adenosine deaminase 2[preprint].622https://doi.org/10.1101/2023.10.25.564037. Posted on bioRxiv October 8, 2024.[preprint].

- 623 21. Rapaport F, et al. Negative selection on human genes underlying inborn errors depends on disease
- outcome and both the mode and mechanism of inheritance. Proceedings of the National Academy of 624 625 Sciences. 2021;118(3):e2001248118.
- 626 22. Boutboul D, et al. Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined 627 immunodeficiency. Journal of Clinical Investigation. 2018;128(7):3071–3087.
- 628 23. Chen L, et al. Comparison of disease phenotypes and mechanistic insight on causal variants in 629 patients with DADA2. Journal of Allergy and Clinical Immunology. 2023;152(3):771-782.
- 630 24. Zavialov A V., et al. Structural basis for the growth factor activity of human adenosine deaminase 631 ADA2. Journal of Biological Chemistry. 2010;285(16):12367–12377.
- 632 25. Asano T, et al. Human STAT3 variants underlie autosomal dominant hyper-IgE syndrome by negative dominance. Journal of Experimental Medicine. 2021;218(8):e20202592. 633
- 634 26. Karczewski KJ, et al. Systematic single-variant and gene-based association testing of thousands of 635 phenotypes in 394,841 UK Biobank exomes. Cell Genomics. 2022;2(9):100168.
- 636 27. Sun BB, et al. Plasma proteomic associations with genetics and health in the UK Biobank. *Nature*. 637 2023;622(7982):329-338.
- 638 28. Kurki MI, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. 639 Nature. 2023;613(7944):508-518.
- 640 29. Alabbas F, et al. Childhood Hodgkin Lymphoma: Think DADA2. J Clin Immunol. 2019;39(1):26–29.
- 641 30. Manhal A, et al. Deficiency of adenosine deaminase 2 leading to recurrent Hodgkin lymphoma: A 642 case report. SAGE Open Med Case Rep. 2024;12. https://doi.org/10.1177/2050313X241260148.
- 643 31. Van Montfrans JM, et al. Phenotypic variability in patients with ADA2 deficiency due to identical 644 homozygous R169Q mutations. Rheumatology (United Kingdom). 2016;55(5):902–910.
- 645 32. Arts K, et al. Warts and DADA2: a Mere Coincidence?. J Clin Immunol. 2018;38(8):836–843.
- 646 33. Drago E, et al. Case Report: Susceptibility to viral infections and secondary hemophagocytic 647 lymphohistiocytosis responsive to intravenous immunoglobulin as primary manifestations of 648 adenosine deaminase 2 deficiency. Front Immunol. 2022;13:937108. 649 https://doi.org/10.3389/fimmu.2022.937108.
- 650 34. Bycroft C, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-209. 651
- 652 35. Keer N, et al. Novel compound heterozygous variants in CECR1 gene associated with childhood onset polyarteritis nodosa and deficiency of ADA2. Rheumatology. 2016;55(6):1145–1147. 653
- 654 36. Carmona-Rivera C, et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis 655 and TNF production in patients with DADA2. Blood. 2019;134(4):395-406.
- 656 37. Franceschi C, et al. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. 657 Nat Rev Endocrinol. 2018;14(10):576-590.
- 658 38. Ahn TS, et al. Whole Exome Sequencing Reveals Pathogenic Variants in ADA2 and FAS Causing 659 DADA2 and ALPS. J Clin Immunol. 2023;43(6):1147-1151.

medRxiv preprint doi: https://doi.org/10.1101/2024.12.09.24317629; this version posted December 11, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

- perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .
- 660 39. Akalu YT, Bogunovic D. Inborn errors of immunity: an expanding universe of disease and genetic architecture [preprint]. Nat Rev Genet. 2024;25(3):184–195. 661
- 662 40. Reinius B, Sandberg R. Random monoallelic expression of autosomal genes: Stochastic 663 transcription and allele-level regulation [preprint]. Nat Rev Genet. 2015;16(11):653–664.
- 664 41. Hashem H, et al. Hematopoietic stem cell transplantation rescues the hematological, 665 immunological, and vascular phenotype in DADA2. Blood. 2017;130(24):2682-2688.
- 666 42. Dzhus M, et al. A Narrative Review of the Neurological Manifestations of Human Adenosine Deaminase 2 Deficiency. J Clin Immunol. 2023;43(8):1916–1926. 667
- 668 43. Van Der Spoel D, et al. GROMACS: Fast, flexible, and free [preprint]. J Comput Chem. 669 2005;26(16):1701-1718.
- 670 44. Lee J, et al. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and 671 CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. J Chem Theory Comput. 672 2016;12(1):405-413.
- 673 45. Jo S, et al. CHARMM-GUI: A web-based graphical user interface for CHARMM. J Comput Chem. 674 2008;29(11):1859-1865.
- 675 46. Izadi S, Anandakrishnan R, Onufriev A V. Building water models: A different approach. Journal of 676 *Physical Chemistry Letters*. 2014;5(21):3863–3871.
- 677 47. Tian C, et al. Ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum 678 Mechanics Energy Surfaces in Solution. J Chem Theory Comput. 2020;16(1):528–552.
- 679 48. Li Z, et al. Systematic Parametrization of Divalent Metal Ions for the OPC3, OPC, TIP3P-FB, and TIP4P-FB Water Models. J Chem Theory Comput. 2020;16(7):4429–4442. 680
- 681 49. Feenstra KA, Hess B, Berendsen HJC. Improving efficiency of large time-scale molecular dynamics simulations of hydrogen-rich systems. J Comput Chem. 1999;20(8):786–798. 682
- 683 50. Hopkins CW, et al. Long-time-step molecular dynamics through hydrogen mass repartitioning. J 684 *Chem Theory Comput.* 2015;11(4):1864–1874.
- 685 51. Araya R. Enriching elementary school mathematical learning with the steepest descent algorithm. 686 Mathematics. 2021;9(11). https://doi.org/10.3390/math9111197.
- 687 52. Páll S, Hess B. A flexible algorithm for calculating pair interactions on SIMD architectures. Comput Phys Commun. 2013;184(12):2641-2650. 688
- 689 53. Darden T, York D, Pedersen L. Particle mesh Ewald: An N·log(N) method for Ewald sums in large 690 systems. J Chem Phys. 1993;98(12):10089–10092.
- 691 54. Hess B. P-LINCS: A parallel linear constraint solver for molecular simulation. J Chem Theory Comput. 692 2008;4(1):116-122.
- 693 55. Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. Journal of Chemical Physics. 2007;126(1). https://doi.org/10.1063/1.2408420. 694
- 695 56. Bernetti M, Bussi G. Pressure control using stochastic cell rescaling. Journal of Chemical Physics. 696 2020;153(11). https://doi.org/10.1063/5.0020514.

- 57. Parrinello M, Rahman A. Polymorphic transitions in single crystals: A new molecular dynamics method. J Appl Phys. 1981;52(12):7182-7190.
- 58. Stein D, et al. Genome-wide prediction of pathogenic gain- and loss-of-function variants from ensemble learning of a diverse feature set. Genome Med. 2023;15(1). https://doi.org/10.1186/s13073-023-01261-9.
- 59. Karczewski KJ, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434-443.
- 60. Shuey MM, et al. Next-generation phenotyping: introducing phecodeX for enhanced discovery research in medical phenomics. Bioinformatics. 2023;39(11). https://doi.org/10.1093/bioinformatics/btad655.
- 61. Giusti G. Adenosine Deaminase. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis (Second Edition). Academic Press; 1974:1092–1099.

Figures 724



726 Figure 1. Pedigree analysis of 10 DADA2 carriers presenting with DADA2 clinical phenotype. A. 727 Pedigrees of seven kindreds showing familial segregation of ADA2 missense variants. M represents 728 mutant. Individuals with unknown genotype are labeled '?'. Black filled symbols represent individuals 729 with 2 pathogenic alleles, half-filled symbols represent individuals with 1 pathogenic allele 'P' 730 represents individuals carrying 1 pathogenic allele with a DADA2 phenotype. B. Schematic representation of the functional domains of the ADA2 protein and the location of the ADA2 variants 731 identified in our cohort (labeled '*'), in previous studies (labeled '~') and in literature (labeled '§'). 732



734

735 Figure. 2 Secretion of ADA2 dimers in homozygous or heterozygous state on non-denaturating gel.

A. ADA2 dimer secretion of HEK293T cells transfected with WT and/or ADA2 variants. Cells and 736 737 supernatant were collected 48h after transfection. B. Quantification of ADA2 secretion in Supernatant 738 of transfected HEK293T cells with wild-type ADA2 or ADA2 variants in homozygous conditions. Bar graphs represent percentage of ADA2 protein secretion relative to wild-type ADA2 100%. 739 С. 740 Quantification of ADA2 secretion of co-transfected HEK293T cells of ADA2 variants together with wild-741 type ADA2 in heterozygous conditions. Bar graphs represent percentage of ADA2 secretion relative to 742 wild-type ADA2 50%. experiments. A-C. Image shown represents 3 independent experiments.

It is made available under a



744

745 Figure 3. Adenosine deaminase activity of ADA2 variants in homozygous or heterozygous state A. 746 Adenosine deaminase activity in whole cell lysate of HEK293T transfected cells with WT and ADA2 747 variants in homozygous conditions. Bar graphs represent the percentage of enzymatic activity relative 748 to wild-type ADA2 100%. B. Adenosine deaminase activity in supernatant of HEK293T transfected cells 749 with WT and ADA2 variants in homozygous conditions. Bar graphs represent the percentage of 750 enzymatic activity relative to wild-type ADA2 100%. C. Adenosine deaminase activity whole cell lysate 751 of HEK293T transfected cells with WT and/or ADA2 variants in heterozygous conditions. Bar graphs 752 represent the percentage of enzymatic activity relative to wild-type ADA2 50%.. D. Adenosine deaminase activity in supernatant of HEK293T transfected cells with WT and/or ADA2 variants. Bar 753 graphs represent the percentage of enzymatic activity relative to wild-type ADA2 50%.. A-D. Data 754 755 represents mean ± SD from 3 independent experiments.



С

757

В











Figure 4. Molecular modeling of ADA2 variants G47A, G47R, G47V, G47W, R169Q, E328K, H424N and 759 760 <u>Y453C.</u>

A. Comparative plots of the different mutations which displays the variability of B-factor values along 761 762 the protein backbone compared to the wild target. Blue backbones represent lower fluctuations 763 compared to the wild target, red backbones represent higher fluctuations. B. Zoom-in of residue 764 R169 in the wild target protein. R169 is shown in magenta. Polar and aromatic interactions are shown 765 as dashed lines. C. Zoom-in of residue E328 in the wild target protein. E328 is shown in magenta. Polar

- interactions are shown as dashed lines. **D.** Zoom-in of residue Y453 in the wild target protein. Y453

768





771 Figure 5. Serum ADA2 enzymatic activity of suspected DADA2 patients.



- 775 the Mann-Whitney U test,*** p<0.0001. B. ADA2 protein secretion in Serum samples of pediatric
- 776 controls, adult controls, DADA2 patients and cohort patients by Western blot. C-D. Quantification of
- 777 ADA2 secretion in Serum samples of pediatric controls, adult controls, DADA2 patients and cohort
- 778 patients. Bar graphs represent percentage of ADA2 protein secretion relative to Pediatric/adult
- 779 controls. Each bar represents mean ± SD from 3 independent experiments.

Tables 780

781 Table. 1 Clinical impact of R169Q in the UK Biobank and Finngen

	Phenotype	UKB	UKB	UKB	UKB	Finnge	Finnge
		(Gen	(Gen	(AZPhewa	(AZPhewa	n OR	n p-
		е	е	s) OR	s) p-value		value
		bass)	bass)				
		OR	p-				
			valu				
			е				
Neurological	Ischemic stroke	1.5	0.4				
	Stroke not						
	specified as		0.3				
	hemorrhage or		0.0				
	infarction	1.5					
	Sequelae of						
	cerebrovascular		0.02				
	disease	5.8					
	Headaches	1.4	0.5				
	Vertigo	15.2	0.04				
	Dizziness and			23.3	0.0013		
	giddiness						
	Vascular dementia	2.2	0,5			4.3	0.002
Cutaneous	Livedoid vasculitis					7.4	0.01
vasculopathy	Other and						
	unspecified		0.6				0.01
	vasculitis limited to	0.4	- / -				
	skin					5.2	
	Raynaud						
	phenomenon/disea		0.4				
	se	3.3					
Immunologica	Selective deficiency						0.005
1/	of immunoglobulin					6.0	0.005
nematological	A					6.8	
	immunoaeticiency						
	with		0.6				0.03
	predominantly	0.4				26	
Othor		0.4	0.7			3.0 12.1	0.02
outen	Other and	0.4	0.7			13.1	0.02
cutaneous							0.01
						07	0.01
	cicatricial alopecia					8.7	

Bone marrow	Other primary					F F	0.02
	thrombocytopenia					5.5	
	Idiopathic						
	thrombocytopenic			75.40	0.008		
	purpura						
Gastrointestin	Intestinal	1.09	0.9			2.96	0.0003
al	malabsorption						
	Ulcerative colitis	3.39	0.02	26.519	0.0062		
Infections	Infective/viral						
	hepatitis	8.6	0.03				
	Viral warts	0.6	0.04			0.9	0.8
	Cytomegaloviral		0.7			0.3	0.6
	disease	0.4	0.7				
Malignancies	Hodgkin	4.4	0.3				
	lymphoma/						
	Hodgkin disease						
	Myeloid leukemia	18.2	0.03				
Other	Liver/biliary/pancre		0.00				
	as problem	14.7	3				
	Chronic liver		0.02				
	hepatitis	23.8					
	Joint disorder			00 17	0.005		
	unspecified			00.47	0.005		
	Hypertrophic			110 20	0.0001		
	cardiomyopathy			110.50	0.0001		

782 OR: Odds ratio.